Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.

Area of Science:

• Pulmonary drug delivery
• Nanotechnology in oncology
• Cancer therapeutics

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of death, with conventional therapies facing limitations like toxicity and resistance.
• Current treatments for NSCLC include chemotherapy and radiotherapy, often with severe side effects and limited efficacy.
• Pulmonary drug delivery systems are emerging as a non-invasive alternative, enabling localized drug administration to the lungs.

Purpose of the Study:

• To review inhalable formulations for targeted lung cancer drug delivery.
• To explore the potential of nano-based systems for enhanced chemotherapy and diagnostics in NSCLC.
• To discuss challenges and considerations for developing effective pulmonary nano-drug delivery systems.

Main Methods:

• Review of current literature on inhalable drug delivery systems for lung cancer.
• Analysis of various nano-based carriers (lipids, liposomes, polymers, inorganic nanocarriers, micelles, microparticles) for pulmonary administration.
• Discussion of drug delivery devices and physiological barriers in pulmonary chemotherapy.

Main Results:

• Inhalable nano-based systems can increase local drug concentration in the lungs, improving antitumor efficacy.
• These systems offer potential for reduced systemic toxicity and improved patient outcomes compared to conventional methods.
• Nano-carriers with sustained release mechanisms show promise in overcoming lung retention and efficacy challenges.

Conclusions:

• Inhalable nano-based drug delivery presents a viable strategy for localized and targeted lung cancer treatment.
• Addressing pharmacological, immunological, and toxicological factors is crucial for successful development.
• Further research into nano-carrier design and delivery devices is essential to overcome physiological barriers and optimize therapeutic outcomes.